RAIN News and Press, Rain Therapeutics Inc. From 05/27/21

NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate over...

Rain Therapeutics shares rise ([[RAIN]] +13.9%) after the company posted first-quarter results and provided a cash position update.The company expects the full year 2021 net cash used in operating and investing activities to be about $50M to $60M and a projected year end cash balanc...

Rain Therapeutics (RAIN): Q1 GAAP EPS of -$1.93 misses by $0.23.As of March 31, 2021, Rain had $53.1M in cash and cash equivalents which does not include the net proceeds from the IPO in April 2021 of $121.9M.The Company expects the full year 2021 net cash used i...

Completed initial public offering ("IPO") with net proceeds of $121.9 million Key appointments to the leadership team, board of directors and scientific advisory board Planned Phase 3 trial initiation in 2H 2021 for RAIN-32 in well-differentiated ("WD")/de-differentiated (...

NEWARK, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the appointment of Rain co-founder Robert Doebele, M.D., Ph.D. as president and chief scientific officer ...

Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI) +8%.Express (EXPR) +7%.Eloxx Pharmac...